Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1378-1383

  Rusten, Espen ^a,b   Rodal, Jan ^b   Bruland, Oyvind S ^b,c   Malinen, Eirik ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CLINICAL ARTICLE; HUMAN; IMAGE ANALYSIS; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; METABOLIC RATE; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; SOFT TISSUE SARCOMA; TREATMENT PLANNING; COMPARTMENT MODEL; DYNAMIC POSITRON EMISSION TOMOGRAPHY; HISTOGRAM; ORGANS AT RISK; PET SCANNER; TREATMENT OUTCOME; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; SARCOMA;

EID: 84884559528     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.813071     Document Type: Article

References (31)

1. Hoshikawa H, Kishino T, Nishiyama Y, Yamamoto Y, YonezakIm, Mori N. Early prediction of local controLin head and neck cancer after chemoradiotherapy by FDGPET. Nucl Med Commun 2011;32:684-9
2. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009;31:195-201
3. BertagnAf, Giubbini R. F18-FDG-PET/CT standardised uptake value thresholDin discriminating benign vs. malignant lesions. Doubts and certainties in the era of evidencebased medicine. Acta Oncol 2012;51:122-44
4. van Elmpt W, De Ruysscher D, Van Der Salm A, Lakeman A, Van Der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation triaLin non-small cell lung cancer. Radiother Oncol 2012;104:67-71
5. van Loon J, van Baardwijk A, Boersma L, Ollers M, Lambin P, De Ruysscher D. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev 2011;37:331-43
6. Ashamalla H, Guirgius A, Bieniek E, Rafla S, Evola A, Goswami G, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:388-95
7. Duprez F, Bonte K, De Neve W, Boterberg T, De Gersem W, Madani I. Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;79:450-8
8. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functionaLimaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009;50:1020-7
9. Ashton E, Riek J. Advanced MR techniques in multicenter clinical trials. J Magn Reson Imaging 2013;37:761-9
10. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007;8:63-74
11. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med MoLimaging 2010;37:1481-9
12. Revheim ME, Kristian A, Malinen E, Bruland OS, Berner JM, Holm R, et al. Intermittent and continuous imatinib in a humaNgIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013;52:776-82
13. Bussink J, Kaanders JH, Van Der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011;8: 233-42
14. Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomicaLimaging in oncology. Nucl Med Commun 2012;33:349-61
15. Lips IM, Van Der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of Afocal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial. Trials 2011;12:255
16. Rusten E, Rodal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic (18)FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta OncoLepub 2012 Dec 3
17. Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: Comparison witHangiogenesis markers and prognostic factors. J Nucl Med 2012;53:512-20
18. Malinen E, Rodal J, Knudtsen IS, Sovik A, Skogmo H.K. Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 2011;50:873-82
19. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDGuptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008;49:517-23
20. Roe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, et al. Preclinical dynamic 18F-FDG PET-tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 2010;49:914-21
21. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in humaNglioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-7
22. Park SG, Lee JH, Lee WA, Han KM. Biologic correlation betweeNglucose transporters, hexokinase-II, Ki-67 and FDGuptake in malignant melanoma. Nucl Med Biol 2012;39:1167-72
23. Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, et al. Relationship betweeNglucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 2005;52:486-90
24. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: Alooking glass for cancer? Nat Rev Cancer 2012;12: 323-34
25. Jansen JF, Schoder H, Lee NY, Stambuk HE, Wang Y, Fury MG, et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: Pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 2012;82:299-307
26. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 2010;14:771-94
27. Gatenby RA, Gillies RJ. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol 2007;39:1358-66
28. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487-93
29. Groenendaal G, Van Den Berg CA, Korporaal JG, Philippens ME, Luijten PR, van Vulpen M, et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010; 95:185-90
30. Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol 2012;105:36-40
31. Flynn RT, Barbee DL, Mackie TR, Jeraj R. Comparison of intensity modulated x-ray therapy anDintensity modulated proton therapy for selective subvolume boosting: A phantom study. Phys Med Biol 2007;52:6073-91